|
For women facing radiation therapy after surgery for breast cancer, the
standard course of treatment typically involves daily radiation
sessions over a period of 6 to 7 weeks. That regimen can be hard to
manage, especially for women already juggling work and child care
schedules or for those living far from treatment centers.
Shorter, and potentially cheaper, courses of radiation may
soon be a real option for some women, according to new research
presented at the annual meeting of the American Society for Therapeutic
Radiology and Oncology (ASTRO).
MammoSite: Promising Results
from Large Trial
The MammoSite system, approved by the US Food and Drug
Administration for the treatment of early stage breast cancer in 2002,
delivers radiation from inside the space left after surgeons remove the breast tumor. Radiation is delivered through seed implants,
which are planted inside a balloon that is placed inside the woman's
breast. The radiation takes about 5-6 days to administer.
The technique is a type of intracavitary brachytherapy,
and is one of several methods of accelerated partial breast
irradiation, or ABPI.
In the study presented at ASTRO, researchers mined registry
data to analyze breast cancer recurrence rates among 1440 women with
early stage breast cancer who had been treated with MammoSite from May
2002 until September 2004. The researchers also looked at whether other
factors, such as tumor location, type, size, and whether the cancer had
spread to lymph nodes, affected results. Of the women who received
treatment, the median age was 65.
After nearly 4 years, researchers saw low rates of breast
cancer recurrence and rates of survival comparable with standard
treatment.
"Not only does it make radiation treatment much more
convenient, it may actually increase the rate of breast conservation,
since some women choose mastectomy because they live too far from the
radiation center and cannot afford the expense of 6 to 7 weeks of
living or traveling to the center," said Peter Beitsch, MD, lead author
of the study and a surgical oncologist at Medical City Dallas Hospital
in Dallas.
"Also, there are many women who for a host of reasons don't
receive the necessary postoperative radiation and the shortened course
should hopefully allow more women to receive the therapy that they
need."
While the results are encouraging, the research is still
preliminary and has yet to be published in a major medical journal.
Longer-term studies are also needed to be certain the MammoSite
technique is equally effective as traditional radiation methods at
preventing breast cancer recurrence. A 10-year clinical trial to
investigate that was launched in 2005. (See "Study to Test Partial Breast Radiation.")
And since the device involves inserting a balloon into the
breast, research is needed to further investigate the cosmetic impact of the procedure.
Shorter Radiation Cycles
The second study looked at whether an accelerated 3-week
schedule of whole-breast
radiation therapy (known as hypofractioned whole breast
irradiation) was just as effective as the conventional
5-week schedule. Between 1993 and 1996, 1234 women were randomly
assigned to receive whole breast radiation over 22 days (622 women) or
35 days (612 women). The women were followed for 12 years.
The researchers found the risk for recurrence at 10 years was
just about the same for both groups: the risk was 6.2% for the group
with the accelerated pace and 6.7% for the 35 day-group. At 10 years,
70% of the women in the accelerated radiation group had good cosmetic
results, compared to 71% in the other group.
"There has been renewed interest in hypofractioned whole
breast irradiation, due to potential radiation advantages, patient
convenience, quality of life, and lower costs. However, long-term
effects were a potential concern," said Timothy Whelan, MD, lead author
of the study and a radiation oncologist at the Juravinski Cancer Centre
at McMaster University in Hamilton, Ontario, Canada, where the research
took place. "We were surprised that the risk of local recurrence and
side effects was so low even at 12 years. Our study shows that this
treatment should be offered to select women treated with early-stage
breast cancer."
While these studies are promising, many doctors still consider
both treatments experimental. Women who are interested in these options
should talk to their doctors and consider participating in clinical
trials. To find a clinical trial, see the American Cancer Society's online Clinical Trial
Matching Service.
"Long-term Results of a Randomized Trial of Accelerated
Hypofractionated Whole Breast Irradiation Following Breast Conserving
Surgery in Women with Node-Negative Breast Cancer." First Author: T.G.
Whelan. International
Journal of Radiation Oncology, Biology, Physics. Abstract
No. 60. Volume 72, Number 1, Supplement, 2008.
"Recurrence and Survival in the American Society of Breast
Surgeons (ASBS) MammoSite® RTS Registry Trial." First Author: P.D.
Beitsch. International
Journal of Radiation Oncology, Biology, Physics. Abstract
No. 5. Volume 72, Number 1, Supplement, 2008.
ACS News Center stories are provided as a source of cancer-related
news and are not intended to be used as
press releases.
|